Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1)

BACKGROUND: To investigate the safety and feasibility of combining neoadjuvant sintilimab (Innovent Biologics, Suzhou, China) and chemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC). METHODS: The study was an investigator-initiated, open-label, non-randomized, single-arm, sin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhenyang, Hong, Zhi-Nuan, Xie, Shuhan, Lin, Wenwei, Lin, Yukang, Zhu, Jiafu, Yang, Xiaojie, Lin, Zhiwei, Lin, Jiangbo, Kang, Mingqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640906/
https://www.ncbi.nlm.nih.gov/pubmed/34926667
http://dx.doi.org/10.21037/atm-21-5381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640906/
https://www.ncbi.nlm.nih.gov/pubmed/34926667
http://dx.doi.org/10.21037/atm-21-5381

Ejemplares similares